-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the US National Institutes of Health clinical trial database, Eli Lilly has initiated the first phase III clinical trial of Eloralintide. Eloralintide is a selective insulin receptor agonist being developed to be administered once a week. This phase III study aimed to evaluate the efficacy and safety of eloralintide versus placebo in obese or overweight subjects with type 2 diabetes.

Zhitongcaijing·12/16/2025 06:25:04
Listen to the news
According to the US National Institutes of Health clinical trial database, Eli Lilly has initiated the first phase III clinical trial of Eloralintide. Eloralintide is a selective insulin receptor agonist being developed to be administered once a week. This phase III study aimed to evaluate the efficacy and safety of eloralintide versus placebo in obese or overweight subjects with type 2 diabetes.